Literature DB >> 30628514

Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain.

Xin Pang1, Zhixia Zhou1, Zhuang Yu2, Lichun Han2, Zhijuan Lin1,3, Xiang Ao1, Chang Liu4, Yuqi He5, Murugavel Ponnusamy1, Peifeng Li1, Jianxun Wang1.   

Abstract

The development of chemotherapeutic drugs resistance such as doxorubicin (DOX) and cisplatin (DDP) is the major barrier in gastric cancer therapy. Emerging evidences reveal that microRNAs (miRNAs) contribute to chemosensitivity. In this study, we investigated the role of miR-633, an oncogenic miRNA, in gastric cancer chemoresistance. In gastric cancer tissue and cell lines, miR-633 expression was highly increased and correlated with down regulation of Fas-associated protein with death domain (FADD). Inhibition of miR-633 significantly increased FADD protein level and enhanced DOX/DDP induced apoptosis in vitro. MiR-633 antagomir administration remarkably decreased tumor growth in combination with DOX in vivo, suggesting that miR-633 targets FADD to block gastric cancer cell death. We found that the promoter region of miR-633 contained putative binding sites for forkhead box O 3 (Foxo3a), which can directly repress miR-633 transcription. In addition, we observed that DOX-induced nuclear accumulation of Foxo3a leaded to the suppression of miR-633 transcription. Together, our study revealed that miR-633/FADD axis played a significant role in the chemoresistance and Foxo3a regulated this pathway in gastric cancer. Thus, miR-633 antagomir resensitized gastric cancer cells to chemotherapy drug and had potentially therapeutic implication.

Entities:  

Keywords:  FADD; Foxo3a; chemosensitivity; gastric cancer; miR-633

Mesh:

Substances:

Year:  2019        PMID: 30628514      PMCID: PMC6380283          DOI: 10.1080/15476286.2019.1565665

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  54 in total

1.  Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.

Authors:  Catherine L Jopling; Minkyung Yi; Alissa M Lancaster; Stanley M Lemon; Peter Sarnow
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

2.  Activation of FOXO3a suggests good prognosis of patients with radically resected gastric cancer.

Authors:  Shan Yu; Yiyi Yu; Yihong Sun; Xuefei Wang; Rongkui Luo; Naiqing Zhao; Wen Zhang; Qian Li; Yuehong Cui; Yan Wang; Wei Li; Tianshu Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  [Association of miRNAs expression profiles with prognosis and relapse in childhood acute lymphoblastic leukemia].

Authors:  Ling Xu; Yan-ni Liang; Xue-qun Luo; Xiao-dan Liu; Hai-xia Guo
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2011-03

Review 4.  Gastric cancer.

Authors:  Eric Van Cutsem; Xavier Sagaert; Baki Topal; Karin Haustermans; Hans Prenen
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

5.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

6.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

Review 7.  Chemotherapy for advanced gastric cancer.

Authors:  Anna Dorothea Wagner; Nicholas Lx Syn; Markus Moehler; Wilfried Grothe; Wei Peng Yong; Bee-Choo Tai; Jingshan Ho; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

8.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

Authors:  K M Tewey; T C Rowe; L Yang; B D Halligan; L F Liu
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

9.  Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells.

Authors:  Léa Tourneur; Sylvie Mistou; Francine-Marie Michiels; Valérie Devauchelle; Laurent Renia; Jean Feunteun; Gilles Chiocchia
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

10.  RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.

Authors:  R R Somasagara; S M Spencer; K Tripathi; D W Clark; C Mani; L Madeira da Silva; J Scalici; H Kothayer; A D Westwell; R P Rocconi; K Palle
Journal:  Oncogene       Date:  2017-08-14       Impact factor: 9.867

View more
  11 in total

1.  NFKB1-miR-612-FAIM2 pathway regulates tumorigenesis in neurofibromatosis type 1.

Authors:  Meng Wang; Zengtao Wang; Xiaolei Zhu; Shibing Guan; Zhibo Liu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-06-13       Impact factor: 2.416

2.  The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.

Authors:  Erez Uzuner; Gizem Tugçe Ulu; Sevim Beyza Gürler; Yusuf Baran
Journal:  Methods Mol Biol       Date:  2022

Review 3.  The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.

Authors:  Zahra Torki; Davood Ghavi; Solmaz Hashemi; Yazdan Rahmati; Dara Rahmanpour; Majid Pornour; Mohammad Reza Alivand
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-12       Impact factor: 3.333

Review 4.  The FOXO family of transcription factors: key molecular players in gastric cancer.

Authors:  Ying Liu; Xiang Ao; Yi Jia; Xiaoge Li; Yu Wang; Jianxun Wang
Journal:  J Mol Med (Berl)       Date:  2022-06-10       Impact factor: 5.606

5.  SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop.

Authors:  Yifei An; Bo Wang; Xin Wang; Guoying Dong; Jihui Jia; Qing Yang
Journal:  Cell Death Dis       Date:  2020-02-12       Impact factor: 8.469

Review 6.  Research Progress in microRNA-Based Therapy for Gastric Cancer.

Authors:  Xu Zhao; Gao-Feng Hu; Yan-Fen Shi; Wei Xu
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

7.  MicroRNA-1249 Targets G Protein Subunit Alpha 11 and Facilitates Gastric Cancer Cell Proliferation, Motility and Represses Cell Apoptosis.

Authors:  Hongzhu Zhang; Tingting Fu; Cuiping Zhang
Journal:  Onco Targets Ther       Date:  2021-02-24       Impact factor: 4.147

Review 8.  Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer.

Authors:  Ying Liu; Xiang Ao; Guoqiang Ji; Yuan Zhang; Wanpeng Yu; Jianxun Wang
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

9.  FOXO3a inhibits nephroblastoma cell proliferation, migration and invasion, and induces apoptosis through downregulating the Wnt/β‑catenin signaling pathway.

Authors:  Cheng Qian; Qiang Liu
Journal:  Mol Med Rep       Date:  2021-09-13       Impact factor: 2.952

Review 10.  Noncoding RNAs in gastric cancer: implications for drug resistance.

Authors:  Ling Wei; Jujie Sun; Nasha Zhang; Yan Zheng; Xingwu Wang; Liyan Lv; Jiandong Liu; Yeyang Xu; Yue Shen; Ming Yang
Journal:  Mol Cancer       Date:  2020-03-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.